Introduction {#s0005}
============

Pancreatic cancer (PC) prevalence has been increasing over several decades, despite advances in testing and treatment methods [@b0005], [@b0010], [@b0015]. Due to a lack of early stage physical symptoms and specific diagnostic biomarkers, most PCs go undetected until progression into late-stage disease [@b0020]. Indeed, fewer than 15% of PCs are resectable by the time of diagnosis, reinforcing the need for biomarkers or predictive tests to evaluate PC risk [@b0025]. While acute and chronic pancreatitis have been shown to be risk factors for pancreatic cancer development [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055], there is currently no way to distinguish the at-risk subpopulation of patients who will ultimately develop PC from those patients whose pancreatitis will resolve or maintain with no progression to cancer [@b0060], [@b0055]. The lack of screening for the patients in this at-risk subpopulation can delay identification of their cancer by up to two years [@b0055], reducing the likelihood that detected cancers will be resectable and respond well to treatment. The disconnect between known risk factors and time of diagnosis reinforces the need for non-invasive screening methods that can detect early neoplastic changes.

Acidosis in the extracellular tumor microenvironment is a common characteristic of most solid tumors [@b0065]. While a definitive biological reason is unclear, cancer cells typically metabolize glucose to lactate via aerobic glycolysis, a phenomenon known as the Warburg effect [@b0070], [@b0075]. Excess intracellular lactate and H^+^ ions resulting from this process are ultimately secreted from the cell, causing acidification in the extracellular tumor microenvironment relative to normal tissues [@b0080]. Thus, extracellular pH (pHe) can be used as a biomarker of cancer detection. Assessments of pHe have been shown to differentiate tumor from healthy tissue in a variety of cancer types, including mouse models of pancreatic ductal adenocarcinoma (PDAC) [@b0085].

While a variety of methods exist for *in vivo* pH measurement, such as PET, optical imaging, and MR spectroscopy, these methods are limited by imaging depth, spatial resolution, and/or a semi-quantitative nature [@b0090]. These issues are improved by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI), one of the first non-invasive imaging techniques that can accurately and precisely measure pHe *in vivo* [@b0095], [@b0100]. CEST MRI is a method by which the coherent magnetic resonances of labile protons in exogenous or endogenous compounds are selectively saturated, followed by exchange of the protons with water, which causes a decrease in the water MRI signal ([Figure 1](#f0005){ref-type="fig"}A). Because the exchange of these saturated protons with protons in water molecules is base-catalyzed, the resultant CEST signal amplitude is pH-dependent ([Figure 1](#f0005){ref-type="fig"}B). AcidoCEST MRI is a subset of this method that uses an exogenous CT agent that has been repurposed for MRI, which has been used for *in vivo* pHe measurements both pre-clinically and clinically [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140]. Our study evaluated the efficacy of acidoCEST MRI in pHe detection of spontaneous murine PC.Figure 1The mechanism of CEST MRI. Iopamidol, a CT agent repurposed for acidoCEST MRI measurements of pH, is shown in this figure. A) Selective saturation of the MRI frequency of an amide proton causes the loss of net coherent MRI signal from the proton. Subsequent chemical exchange of the amide proton with a proton on water causes the saturation to be transferred to the water. B) A Z-spectrum, also known as a CEST spectrum, is generated by selectively saturating MRI frequencies and detecting the coherent water MRI signal amplitude.

The determination of pHe in PC is further complicated by its inflammatory nature. One common method of identification and staging of cancer, \[18F\]-fluorodeoxyglucose positron emission tomography (FDG-PET), can be confounded by the presence of inflammation, as both inflammation and malignant tumors have increased glucose uptake [@b0145], [@b0150]. Inflammation is known to lower pHe, although this decrease in pHe is expected to be mild. Therefore, we hypothesized that inflammation of the pancreas, or pancreatitis, causes only a mild decrease in tissue pHe, while PC has a lower pHe than pancreatitis. Furthermore, previous studies with acidoCEST MRI have not evaluated the overall effect of inflammation on tissue pHe. Therefore, we also hypothesized that acidoCEST MRI can measure a statistically significant difference in pHe between pancreatitis and PC.

In this preliminary study, we sought to investigate the ability of acidoCEST MRI to detect PDAC in the presence of an inflammatory background. To perform this study, we induced pancreatitis in a KC model through treatment with caerulein, which evolves to form pancreatic tumors [@b0155], [@b0160]. We also induced pancreatitis in wild-type mice as a control. We measured *in vivo* pHe prior to caerulein treatment, during pancreatitis, and during the development of PDAC. We evaluated our results to determine if acidoCEST MRI can distinguish PDAC from pancreatitis, and whether acidoCEST MRI can prognosticate pancreatitis that progresses to pancreatic cancer.

Material and methods {#s0010}
====================

Mouse models {#s0015}
------------

Male and female C57BL/6J mice (WT) (The Jackson Laboratory, Bar Harbor, ME, USA) and Kras^LSL.G12D/+^; PdxCre (KC) mice were used for all studies, as prepared by the Experimental Mouse Shared Resource of the University of Arizona Cancer Center, Tucson, AZ. To induce pancreatic inflammation, 10 week old WT and KC mice were injected intraperitoneally into the lower right quadrant with 50 µg/kg/bw of caerulein (Sigma-Aldrich, St. Louis, MO, USA) dissolved in PBS for a 100 µL total injection volume. Caerulein aliquots for mouse dosing were diluted from a stock solution of 100 µg/mL caerulein in PBS. Mice were made to fast for 12 h prior to injections and were injected with hourly intervals of 7 doses, followed by 48 h of rest and 7 additional hourly injections. KC mice that were injected with caerulein developed pancreatic tumors within 5 weeks. A total of 5, 5, 3, and 11 mice were used for the PBS-treated wild type, caerulein-treated wild-type, PBS-treated KC, and caerulein-treated KC cohorts, respectively. A greater number of mice in the caerulien-treated KC chort was used to anticipate potential mouse death before the end of the study due to pancreatic tumor load.

Mice were anesthetized with 1--3% isofluorane in 1 L/min oxygen gas prior to imaging, and maintained at 1.5--2.0% isoflurane during imaging. To deliver the contrast agent bolus and infusion, a tail vein was catheterized with a 27 gauge needle, which was attached to an injection line that extended outside the MRI magnet. Mouse body temperature was monitored using a fiber-optic rectal probe and was maintained at 37 ± 0.5 °C. Mouse respiration was monitored using a pneumatic sensor and was maintained between 30 and 50 breaths per minute.

MRI acquisitions {#s0020}
----------------

MRI scans were performed with a 7 T Bruker Biospec MRI scanner with a 20 cm bore and 72 mm transceiver volume coil (Bruker Biospin, Inc., Bilarica, Massachusetts, USA). Anatomical images were first acquired to locate the pancreas using a Multi-Slice Multi-Echo (MSME) MRI acquisition method, with a 2000 ms repetition time, 10.36 ms effective echo time, 128x96 matrix size, 6.4x4.8 cm field of view, 453x453 µm^2^ in-plane resolution, and 1 mm slice thickness. All anatomical MR images were performed using respiration gating to minimize motion artifacts.

AcidoCEST MR images of the pancreas were then acquired with four repetitions of the a CEST-FISP pulse sequence, followed by intravenous injection of 200 µL of 370 mg of iodine per mL of iopamidol (Isovue, Bracco Imaging S.p.A., Milan, Italy). The injection line was then connected to an infusion pump which delivered 400 µL/h of contrast agent for the remainder of the scanning period. After contrast agent bolus injection and during contrast agent infusion, mice were scanned with six repetitions of the acidoCEST MRI sequence. All acquisitions of the acidoCEST sequence had a 4.16 ms repetition time, 1.88 ms echo time, a 128 × 96 matrix size, 6.4 × 4.8 cm field of view, 453 × 453 µm^2^ in-plane resolution, 2 mm slice thickness, 6 s CEST saturation time, 3.5 µT saturation power, and continuous wave, rectangular pulse shape, iteratively applied at 40 saturation frequencies. All acidoCEST MR images were performed using respiration gating to minimize motion artifacts as previously reported [@b0130], [@b0135].

MRI analyses {#s0025}
------------

AcidoCEST MR images were analyzed using previously established methods [@b0100], [@b0130]. Briefly, pre-injection images at the same saturation frequency were averaged and the signal-to-noise ratio was improved with Gaussian spatial smoothing. Post-injection images were processed using the same procedure. The averaged pre-injection images were subtracted from the averaged post-injection images at the same saturation frequency to eliminate endogenous CEST signals. The resulting CEST spectra for each pixel were fit with the Bloch-McConnell equations that were modified to include pH as a fitting variable. Pixels with contrast above 2√2 multiplied by the standard deviation of scan noise were considered to have a 95% probability of representing the contrast agent. Additionally, only pHe values inside the range of 6.3--7.4 pH units were included in the mapping, as analysis of phantom data proved measurements within this range to be most reliable. Statistical significance, or the absence of this significance, was evaluated using a Students two-tailed t-test with equal variance. A value of p ≤ 0.05 was considered to be statistically significant.

Immunohistochemistry {#s0030}
--------------------

Upon completion of imaging, mice were sacrificed and pancreases were harvested. Tissue was fixed in 10% buffered formalin for 12 h before transfer to 70% ethanol. Tissue was then embedded in paraffin and processed with the Leica ASP6025 Automatic Tissue Processor (Leica Biosystems, Buffalo Grove, IL, USA) for IHC. Tissue was cut in 3 µm thick sections. A total of 8, 12, 8, and 15 tissue samples were stained for the PBS-treated wild type, caerulein-treated wild-type, PBS-treated KC, and caerulein-treated KC cohorts, respectively. Tissues were stained with anti-Ki67, anti-CD45, or anti-CK19 antibodies (Abcam, Cambridge, MA, USA), which indicate neoplasia, inflammation, and ductal hyperplasia, respectively. Digital micrographs were captured using a widefield light microscope (AxioZoom16 (AZ16), Zeiss Microscopy, Jena, Germany). Histology for all cohorts was conducted after the 5 week imaging time point.

Results {#s0035}
=======

We used a T~2~-weighted, anatomical MRI to localize the pancreas and pancreatic tumors ([Figure 2](#f0010){ref-type="fig"}). A 10.36 ms effective echo time enhanced the T~2~ weighting of the image contrast, which improved the tissue visualization. To improve the contrast-to-noise (CNR) of the acidoCEST MR images, we acquired four CEST image sets prior to injection and six image sets after injection, which required 30--40 min, in which the exact time depended on the breathing rate of the mouse due to the need for prospective respiratory gating ([Figure 3](#f0015){ref-type="fig"}). Only 5% of the 40 acidoCEST MRI scans performed with WT mice did not yield usable data, primarily due to motion artifacts that were not adequately suppressed by respiratory gating. For comparison, 12% of the acidoCEST MRI scans performed on KC mice did not yield usable data, primarily due to mouse death while being imaged under anesthesia. Mice with a heavy tumor load were particularly susceptible to death under anesthesia, especially caerulein-treated KC mice in weeks 5 and 8. To reduce the burden of multiple imaging timepoints on these mice, not all the mice imaged at 8 weeks were imaged at 5 weeks. The numbers of successful acidoCEST MRI scans for each cohort at each time point are listed in [Figure 4](#f0020){ref-type="fig"}, relative to the 5, 5, 3, and 11 mice that were used for the PBS-treated wild type, caerulein-treated wild-type, PBS-treated KC, and caerulein-treated KC cohorts, respectively.Figure 2Anatomical MRI localized the pancreas and pancreatic tumors. A MSME MRI acquisition method with a 10.36 msec effective TE resolved the pancreas and pancreatic tumor in a KC model treated with caerulein, as highlighted with a white arrow.Figure 3Parametric maps of pHe. Parametric maps are shown at pretreatment and at 5 weeks post-treatment for the PBS-treated wild-type (PBS WT), caerulein-treated wild-type (CAE WT), PBS-treated KC (PBS KC), and caerulein-treated KC (CAE KC) cohorts.Figure 4Average pHe measurements. The mean pHe value of each mouse was measured, and the mean and standard deviation of the mice in each cohort was then plotted in the histogram, for PBS-treated wild-type (PBS WT), caerulein-treated wild-type (CAE WT), PBS-treated KC (PBS KC), and caerulein-treated KC (CAE KC) cohorts. Error bars represent the standard deviation. The number of values for each average and standard deviation are listed on each histogram bar.

AcidoCEST MRI measured average pHe values that were not significantly different before treatment with PBS or caerulein in the WT and KC models ([Figure 4](#f0020){ref-type="fig"}). The average pHe did not significantly change over time for the PBS-treated WT, caerulein-treated WT, or PBS-treated KC cohorts. The average pHe values of these three cohorts had a narrow range from 6.92 to 7.05 pHe units (except for the caerulein-treated WT cohort that had an average pHe of 6.85 units). For comparison, the caerulein-treated KC cohort had an average pHe of 6.85 to 6.92 before and during the first 48 h of treatment, followed by a decrease to 6.79 units at 5 weeks when pancreatic tumors were detected with anatomical MRI. This lower pHe was sustained at the 8-week time point, with an average pHe value of 6.75 units. Due to the standard deviation of these measurements that ranged between 0.4 and 0.21 pHe units, and the relative low number of successful acidoCEST MRI scans of pancreatic tumors, this decrease in pHe observed in pancreatic tumors was not statistically significant relative to pHe measurements made at earlier time points with this cohort, or relative to other cohorts at the 5-week time point.

Histopathological validation showed that the WT mice treated with PBS or caerulein did not have pancreatic tumors ([Figure 5](#f0025){ref-type="fig"}). These cohorts displayed a lack of Ki67 stain for high cell proliferation or CK19 stain for ductal tumor cells. Instead, these WT cohorts showed evidence for inflammation due to CD45 staining at 5 weeks after treatment. Histopathology showed evidence of high cell proliferation, ductal cell morphology, and inflammation in both the PBS-treated and caerulein-treated KC cohorts. The high cell proliferation and ductal cell morphology in the caerulein-treated KC cohort correlated with the presence of pancreatic tumors detected by MRI. The high cell proliferation, ductal cell morphology, and inflammation detected with histopathology in the PBS-treated KC cohort were unexpected, because anatomical MRI did not detect pancreatic tumors in this cohort.Figure 5Histopathological validation of the treated models. Ki67 staining was used to evaluate cell proliferation. CK19 staining was used to identify duct cells. CD45 staining was used as an indicator of inflammation. The wild type mice showed no evidence for tumors or inflammation. Caerulein-treated KC mice showed evidence for pancreatic tumors and inflammation, which matched the presence of pancreatic tumors detected with MRI. PBS-treated KC mice showed evidence for high cell proliferation, ductal cell morphology, and inflammation, despite the absence of pancreatic tumors detected with MRI.

Discussion {#s0040}
----------

In this preliminary study, we showed that acidoCEST MRI can measure pHe in the pancreas and in pancreatic tumors. AcidoCEST MRI requires a high concentration of iopamidol to be delivered to tissues and tumors, estimated to be 7--10 mM at 7 T magnetic field strengths based on our past Bloch-fitting analyses that include concentration as a fitting parameter [@b0100], [@b0130]. We show that a sufficient concentration of agent was delivered to pancreas tissues in a variety of disease states for pHe measurements with acidoCEST MRI.

Our results showed that acidoCEST MRI can distinguish pancreatitis from PDAC in this murine model. However, our studies were not able to differentiate between pancreatitis in WT mice that subsequently resolved and pancreatitis in KC mice that progressed to PDAC, suggesting that tumor pHe is not a biomarker that can predict the progression of pancreatitis to PDAC. Follow up studies with pHe measurements and histology at additional early time points could further interrogate differences between models of pancreatitis that do and do not progress to PDAC. Additionally, other inflammatory models of cancer could be compared to these results from our studies of PDAC.

Several difficulties in using this method to measure pH in the pancreas became apparent during this study. Primarily, acidoCEST MRI was not able to detect tumors in untreated KC mice, despite histology showing the presence of lesions. This may be due to the small size of the pancreatic lesions, which may have been in an early disease state relative to lesions in the treated KC mice. Difficulty locating smaller lesions was complicated by the limited spatial resolution of small animal MRI [@b0095]. In future studies, improved resolution may facilitate the selection of the region of interest (ROI) in the images that represent the pancreas and pancreatic tumor. Additionally, our acidoCEST MRI method used a slice thickness of 2 mm, which may cause partial volume effects in which a 3D voxel contains a mixture of tissue types, such as healthy and diseased tissue. Improving the contrast-to-noise ratio of the acidoCEST technique should allow future studies to use a thinner slice thickness that can lead to a more tissue-selective ROI. The improved resolution of acidoCEST MRI can also facilitate spatial registration with histology results, and can also facilitate investigations that correlate quantitative acidoCEST MRI with quantitative histopathology. Future studies would also be facilitated by using an alternative species with a larger pancreas, such as a rat, to improve the localization of pancreatic lesions.

Progression of PDAC in the untreated KC mice occurred faster than anticipated. While previous characterizations of the model suggested that PanIN lesions would first appear at 8 weeks in this model [@b0160], we found that pancreatic tumors had developed in the untreated KC mice as early as 5 weeks. Fortunately, the timing of our acidoCEST MRI studies still captured the lower pHe during the development of the pancreatic tumors in this model. Interestingly, the average pHe was lower for the first 48 h after caerulein treatment of the KC model relative to the other models (except for the 48-h time point of the caerulein-treated wild-type mice), which may indicate that the level of inflammation caused by caerulein may be higher in KC mice. Future studies should consider characterizing the level of caerulein-induced inflammation at earlier time points to better understand how inflammation affects the development of tumors in various mouse models of pancreatic cancer.

Conclusions {#s0045}
===========

AcidoCEST MRI was able to measure the pHe of the pancreas and tumor tissues during progression of pancreatitis to pancreatic cancer in a caerulein-treated KC model. Pancreatic tumors had lower pHe than the pancreatitis. However, pHe could not differentiate between pancreatitis that did or did not progress to pancreatic cancer. Therefore, acidoCEST MRI is a promising technique for improving the specificity of distinguishing cancer from inflammation, but may not be able to prognosticate future development of cancer in patients with pancreatitis.

Appendix A. Supplementary data {#s0060}
==============================

The following are the Supplementary data to this article:Supplementary data 1
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